JP7796013B2 - カルシウム感知受容体アゴニスト化合物及びその使用 - Google Patents

カルシウム感知受容体アゴニスト化合物及びその使用

Info

Publication number
JP7796013B2
JP7796013B2 JP2022534636A JP2022534636A JP7796013B2 JP 7796013 B2 JP7796013 B2 JP 7796013B2 JP 2022534636 A JP2022534636 A JP 2022534636A JP 2022534636 A JP2022534636 A JP 2022534636A JP 7796013 B2 JP7796013 B2 JP 7796013B2
Authority
JP
Japan
Prior art keywords
peptide
arg
compound
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504904A5 (https=
JP2023504904A (ja
Inventor
方舟 呉
瑾 張
菲 高
然 呉
成 廖
雷 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tuo Jie Biopharmaceutical Co Ltd
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of JP2023504904A publication Critical patent/JP2023504904A/ja
Publication of JP2023504904A5 publication Critical patent/JP2023504904A5/ja
Application granted granted Critical
Publication of JP7796013B2 publication Critical patent/JP7796013B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022534636A 2019-12-09 2020-12-08 カルシウム感知受容体アゴニスト化合物及びその使用 Active JP7796013B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911250088.1 2019-12-09
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (3)

Publication Number Publication Date
JP2023504904A JP2023504904A (ja) 2023-02-07
JP2023504904A5 JP2023504904A5 (https=) 2023-12-14
JP7796013B2 true JP7796013B2 (ja) 2026-01-08

Family

ID=76328843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534636A Active JP7796013B2 (ja) 2019-12-09 2020-12-08 カルシウム感知受容体アゴニスト化合物及びその使用

Country Status (11)

Country Link
US (1) US20230041996A1 (https=)
EP (1) EP4091623A4 (https=)
JP (1) JP7796013B2 (https=)
KR (1) KR20220110789A (https=)
CN (2) CN114222578B (https=)
AU (1) AU2020399030B2 (https=)
BR (1) BR112022011127A2 (https=)
CA (1) CA3159744A1 (https=)
MX (1) MX2022006892A (https=)
TW (1) TW202122410A (https=)
WO (1) WO2021115272A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022257940A1 (zh) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
EP4353248A4 (en) * 2021-06-08 2024-10-23 Beijing Tuo Jie Biopharmaceutical Co. Ltd. CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500990A (ja) 2009-07-29 2013-01-10 カイ・ファーマシューティカルズ・インコーポレイテッド 副甲状腺ホルモンを低減する治療剤
JP2014508103A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
JP2014522414A (ja) 2011-06-08 2014-09-04 カイ・ファーマシューティカルズ・インコーポレイテッド 血清リンを調節するための治療剤
JP2015502346A (ja) 2011-11-10 2015-01-22 カイ・ファーマシューティカルズ・インコーポレイテッドＫａｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． カルシウム模倣薬およびその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407097A (pt) * 2003-04-23 2006-01-24 Japan Tobacco Inc Antagonista do casr
EP2643292A1 (en) * 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500990A (ja) 2009-07-29 2013-01-10 カイ・ファーマシューティカルズ・インコーポレイテッド 副甲状腺ホルモンを低減する治療剤
JP2014508103A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
JP2014522414A (ja) 2011-06-08 2014-09-04 カイ・ファーマシューティカルズ・インコーポレイテッド 血清リンを調節するための治療剤
JP2015502346A (ja) 2011-11-10 2015-01-22 カイ・ファーマシューティカルズ・インコーポレイテッドＫａｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． カルシウム模倣薬およびその使用方法

Also Published As

Publication number Publication date
CN114222578B (zh) 2024-06-25
KR20220110789A (ko) 2022-08-09
AU2020399030B2 (en) 2026-04-09
CN118496313A (zh) 2024-08-16
AU2020399030A1 (en) 2022-06-23
CN114222578A (zh) 2022-03-22
TW202122410A (zh) 2021-06-16
BR112022011127A2 (pt) 2022-08-23
JP2023504904A (ja) 2023-02-07
EP4091623A1 (en) 2022-11-23
WO2021115272A1 (zh) 2021-06-17
EP4091623A4 (en) 2024-01-03
CA3159744A1 (en) 2021-06-17
MX2022006892A (es) 2022-10-07
US20230041996A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
JP6995933B2 (ja) インターロイキン２３受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
AU2002336783B2 (en) Cyclic peptides as G-protein-coupled receptor antagonists
AU2004251616A1 (en) Melanocortin receptor 4(MC4) agonists and their uses
CA3220871A1 (en) Hepcidin mimetics for treatment of hereditary hemochromatosis
CN102397558A (zh) Exendin-4类似物的定位聚乙二醇化修饰物及其用途
CA3091993A1 (en) Compstatin analogues and their medical uses
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
CN116157413A (zh) 阿普拉鲁肽的制造、配制和给药
BRPI0619399B1 (pt) Derivado de metastina ou um sal do mesmo, e, medicamento
JP7796013B2 (ja) カルシウム感知受容体アゴニスト化合物及びその使用
EP1422240A2 (en) Analogs of nociceptin
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
KR102057508B1 (ko) 혈청 인을 조절하는 치료제
EP2460826B1 (en) Motilin-like peptide compound having transmucosal absorbability imparted thereto
AU2017254754B2 (en) PEGylated bioactive peptides and uses thereof
WO2022257940A1 (zh) 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
RU2827834C1 (ru) Соединение, представляющее собой агонист кальций-чувствительного рецептора, и его применение
HK40069562A (en) Calcium-sensing receptor agonist compound and application thereof
HK40069562B (zh) 钙敏感受体激动剂化合物及其应用
CN115057910A (zh) 补体活性调节剂，其制备方法及医药用途
WO2022257958A1 (zh) 一种钙敏感受体激动剂的组合物及其应用
TW202608907A (zh) 肽類似物及使用其之方法
EA049126B1 (ru) Аналоги компстатина и пути их медицинского применения
HK40046538A (en) Gip/glp1 co-agonist compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251222

R150 Certificate of patent or registration of utility model

Ref document number: 7796013

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150